Josephine Drijver

Josephine Drijver

Auto-generated profile, based on publicly available information

Josephine Drijver

Princess Máxima Center for Pediatric Oncology Utrecht the Netherlands

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
MKMartin Klein
Martin Klein
ADA Josephine Drijver
A Josephine Drijver
MBMartin J. Van Den Bent
Martin J. Van Den Bent
JBJacolien C Bromberg
Jacolien C Bromberg
KHKhê Hoang-Xuan
Khê Hoang-Xuan
BBBrigitta G Baumert
Brigitta G Baumert
EORTC study 22033–26033 showed no difference in progression-free survival between high-risk low-grade glioma receiving either radiotherapy (RT) or temozolomide (TMZ) chemotherapy alone as primary treatment. Considering the potential long-term deleterious impact of RT on memory functioning, this study aims to determine whether TMZ is associated with less impaired memory functioning. Using the Visual Verbal Learning Test (VVLT), memory functioning was evaluated at baseline and subsequently every 6 months. Minimal compliance for statistical analyses was set at 60%. Conventional indices of memory performance (VVLT Immediate Recall, Total Recall, Learning Capacity, and Delayed Recall) were used as outcome measures. Using a mixed linear model, memory functioning was compared between treatment arms and over time. Neuropsychological assessment was performed in 98 patients (53 RT, 46 TMZ). At 12 months, compliance had dropped to 66%, restricting analyses to baseline, 6 months, and 12 months. At baseline, patients in either treatment arm did not differ in memory functioning, sex, age, or educational level. Over time, patients in both arms showed improvement in Immediate Recall (P = 0.017) and total number of words recalled (Total Recall; P < 0.001, albeit with delayed improvement in RT patients (group by time; P = 0.011). Memory functioning was not associated with RT gross, clinical, or planned target volumes. In patients with high-risk low-grade glioma there is no indication that in the first year after treatment, RT has a deleterious effect on memory function compared with TMZ chemotherapy.

5 May 2025 in EJC Paediatric Oncology
Verified
Journal Article
Open access
JBJessica Beamish
Jessica Beamish
JDJosephine Drijver
Josephine Drijver
MPMarita Partanen
Marita Partanen

1 April 2021 in JMIR Research Protocols
Verified
Journal Article
Open access
ADA Josephine Drijver
A Josephine Drijver
JRJaap Reijneveld
Jaap Reijneveld
LWLinda Wesselman
Linda Wesselman
MKMartin Klein
Martin Klein
Background: A high percentage of patients with cancer experience cognitive impairment after cancer treatment, resulting in a decreased health-related quality of life and difficulty returning to work. Consequently, there is a need for effective treatment options to improve cognitive functioning in these patients. In a healthy aging population, multidomain web-based lifestyle interventions have been found to be effective in preventing cognitive decline and improving cognitive functioning. Objective: This study aims to investigate the feasibility and effectiveness of the web-based lifestyle intervention Mijn Fitte Brein (My Fit Brain [MFB]) on cognitive functioning in patients with cancer returning to work. Methods: The study consists of a feasibility study (N=10), followed by a randomized controlled trial (RCT; N=220). Patients will be recruited by their occupational physicians after their return to work following cancer treatment. Mijn Fitte Brein is organized into 4-week cycles in which patients set a lifestyle goal using the Goal Attainment Scale, receive weekly tips and support, and finally evaluate whether they succeeded in achieving this goal. Lifestyle goals are based on 6 domains: physical exercise, diet, sleep, stress, alcohol use, and smoking. In the feasibility study, data on user experience (structured interview) and usability, assessed with the Post-Study System Usability Scale, will be collected and used to optimize Mijn Fitte Brein. In the RCT, patients will be randomized 1:1 between an intervention group and a control group. Patients will be assessed at baseline, 3 months, and 6 months. The primary outcome measure is subjective cognitive functioning, assessed with the Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog). Secondary outcome measures are lifestyle, objective cognitive functioning, and work and psychosocial factors. Results: Recruitment for the feasibility study has started in February 2020. As of July 2020, however, no patients have been enrolled (due to COVID-19 restrictions). The findings of the feasibility study will be used to optimize the Mijn Fitte Brein intervention. Enrollment for the RCT will continue when possible. The feasibility study will take 6 months (including making adjustments to the intervention), and the RCT will take 2 years. The final results are expected in 2024. The results of the feasibility study and the RCT will be published in peer-reviewed journals. Conclusions: This is the first time the feasibility and efficacy of a multidomain web-based lifestyle intervention will be studied in patients with cancer. If Mijn Fitte Brein is found to be effective in decreasing cognitive complaints in these patients returning to work, it will be a promising treatment option because of being both affordable and accessible.

20 July 2020 in JMIR Preprints
Verified
Preprint
Open access
ADA Josephine Drijver
A Josephine Drijver
JRJaap Reijneveld
Jaap Reijneveld
LWLinda Wesselman
Linda Wesselman
MKMartin Klein
Martin Klein
BACKGROUND A high percentage of patients with cancer experience cognitive impairment after cancer treatment, resulting in a decreased health-related quality of life and difficulty returning to work. Consequently, there is a need for effective treatment options to improve cognitive functioning in these patients. In a healthy aging population, multidomain web-based lifestyle interventions have been found to be effective in preventing cognitive decline and improving cognitive functioning. OBJECTIVE This study aims to investigate the feasibility and effectiveness of the web-based lifestyle intervention Mijn Fitte Brein (My Fit Brain [MFB]) on cognitive functioning in patients with cancer returning to work. METHODS The study consists of a feasibility study (N=10), followed by a randomized controlled trial (RCT; N=220). Patients will be recruited by their occupational physicians after their return to work following cancer treatment. Mijn Fitte Brein is organized into 4-week cycles in which patients set a lifestyle goal using the Goal Attainment Scale, receive weekly tips and support, and finally evaluate whether they succeeded in achieving this goal. Lifestyle goals are based on 6 domains: physical exercise, diet, sleep, stress, alcohol use, and smoking. In the feasibility study, data on user experience (structured interview) and usability, assessed with the Post-Study System Usability Scale, will be collected and used to optimize Mijn Fitte Brein. In the RCT, patients will be randomized 1:1 between an intervention group and a control group. Patients will be assessed at baseline, 3 months, and 6 months. The primary outcome measure is subjective cognitive functioning, assessed with the Functional Assessment of Cancer Therapy–Cognitive Function (FACT-Cog). Secondary outcome measures are lifestyle, objective cognitive functioning, and work and psychosocial factors. RESULTS Recruitment for the feasibility study has started in February 2020. As of July 2020, however, no patients have been enrolled (due to COVID-19 restrictions). The findings of the feasibility study will be used to optimize the Mijn Fitte Brein intervention. Enrollment for the RCT will continue when possible. The feasibility study will take 6 months (including making adjustments to the intervention), and the RCT will take 2 years. The final results are expected in 2024. The results of the feasibility study and the RCT will be published in peer-reviewed journals. CONCLUSIONS This is the first time the feasibility and efficacy of a multidomain web-based lifestyle intervention will be studied in patients with cancer. If Mijn Fitte Brein is found to be effective in decreasing cognitive complaints in these patients returning to work, it will be a promising treatment option because of being both affordable and accessible. CLINICALTRIAL Netherlands Trial Register NL8407; https://www.trialregister.nl/trial/8407 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/22670

18 July 2026 in Journal of Neuropsychology
Verified
Journal Article
Open access
PDF file
JBJessica Beamish
Jessica Beamish
RDRiley M. Damiano
Riley M. Damiano
JDJosephine Drijver
Josephine Drijver
FAFemke Aarsen
Femke Aarsen
MGMartha A Grootenhuis
Martha A Grootenhuis
MPMarita Partanen
Marita Partanen
Neurocognitive impairments are common in paediatric central nervous system (CNS) tumours and can relate to clinical and demographic factors. The impact of social or environmental factors, such as family psychosocial risk, is less well understood. We examined neurocognitive functioning in children with CNS tumours shortly after diagnosis and associations with psychosocial risk. This cohort study included children who underwent neuropsychological assessments within three months of diagnosis. Proportion, chi‐square and t ‐tests were used to compare neurocognitive outcomes to norms and evaluate prevalence of neurocognitive impairment (International Cognition and Cancer Task Force criteria: two scores at z ≤ −1.5, one score at z ≤ −2 or both). Regression analyses examined associations between psychosocial risk, age at diagnosis and neurocognitive outcomes, controlling for medical factors. We included 125 children (47 females; mean age at diagnosis = 9.7 years) assessed at an average of 2.08 months after diagnosis. A larger proportion of patients demonstrated neurocognitive impairments than normative expectations ( p = .002), with a greater likelihood for children from increased psychosocial risk groups ( p = .014). Increased psychosocial risk was associated with lower parent‐reported executive functioning ( p = .028), but not with other neurocognitive outcomes. Midline tumour location was related to better working memory; history of obstructive hydrocephalus was related to poorer verbal memory and chemo/radiotherapy initiation was related to poorer processing speed ( p 's < .05). A sub‐group of children with CNS tumours show neurocognitive impairments shortly after diagnosis. Children with increased family psychosocial risk were at higher risk of impairment. Psychosocial risk can help identify neurocognitively vulnerable children, highlighting the importance of both neuropsychological and psychosocial screening.